Questions around this news
What do the presentations cover?
The release says the presentations will highlight results from a long-term treatment study and a comparative analysis of HyBryte versus Valchlor. It describes the results as positive and says they support HyBryte’s potential as a treatment option for cutaneous T-cell lymphoma, but provides no specific study methods or outcome figures.
What is cutaneous T-cell lymphoma?
Cutaneous T-cell lymphoma, or CTCL, is a group of uncommon non-Hodgkin lymphomas that affect T cells and primarily involve the skin. Symptoms and disease course vary by subtype. Diagnosis and treatment decisions generally involve clinicians with expertise in blood cancers or skin diseases.
How does photodynamic therapy work?
Photodynamic therapy uses a light-sensitive substance and a specific wavelength of light to produce a reaction that can damage targeted cells. The substance may be applied to the skin or delivered another way, depending on the treatment. The approach and its suitability depend on the condition and the therapy being used.
Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026, ahead of the American Academy of Dermatology Annual Meeting. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor(R), supporting HyBryte(TM) potential as a therapeutic option for CTCL.
To view the full press release, visit https://ibn.fm/iTepg
About Soligenix
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behcet’s Disease.
Our Public Health Solutions business segment includes development programs for RiVax(R), our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
Soligenix says new data on HyBryte, its investigational treatment for cutaneous T-cell lymphoma (CTCL), will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026. The workshop takes place ahead of the American Academy of Dermatology Annual Meeting. According to the company, presentations will cover findings from a long-term treatment study and an analysis comparing HyBryte with Valchlor. Soligenix characterizes the results as supportive of HyBryte’s potential role in CTCL treatment. The company describes HyBryte, also identified as SGX301 or synthetic hypericin sodium, as a photodynamic therapy using visible light. It says regulatory approvals would be sought following successful completion of a second Phase 3 study.
Key takeaways
- Soligenix says HyBryte data will be presented at the USCLC Workshop on March 26, 2026.
- Planned presentations will discuss long-term treatment findings and a comparison with Valchlor.
- The workshop precedes the American Academy of Dermatology Annual Meeting.
- Soligenix identifies HyBryte as SGX301, a visible-light photodynamic therapy for CTCL.
SEC filings
Earlier from Soligenix
- Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
- Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
- Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease
- Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
